Ascelia Pharma – Presentation of interim Q3 2025 report
You can already sign up for the event and submit your questions. You don’t need to attend live to send in your questions for the presentation.
Ascelia Pharma is expected to release its Q3 2025 interim report on 5 November 2025. Join us for a live presentation with Deputy CEO Julie Waras Brogren from Ascelia Pharma the following day at 12:00 PM CET, where she will present the financial results for the first nine months of 2025. Participants will have the opportunity to ask questions and gain insights into the company’s latest developments.
Since the release of the H1 2025 results, the company has reached one of this year’s key milestones with the submission of the NDA for Orviglance. Furthermore, Ascelia Pharma has completed a directed share issue raising approximately SEK 30 million, extending its cash runway into Q4 2026, beyond the expected timeline for the FDA response, and thereby de-risking the near-term funding outlook.
In addition to the financial results, the presentation is expected to include a discussion on upcoming partnering activities related to Orviglance, which could represent the next major trigger for the company.
About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. Ascelia Pharma has two drug candidates in clinical development – Orviglance® (Mangoral) and Oncoral. The company is headquartered in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement / Michael Friis, 09.00 AM CET, 14 October 2025.
